These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 25423590)

  • 1. Novel Inhaled Combination Powder Containing Amorphous Colistin and Crystalline Rifapentine with Enhanced Antimicrobial Activities against Planktonic Cells and Biofilm of Pseudomonas aeruginosa for Respiratory Infections.
    Zhou QT; Sun SP; Chan JG; Wang P; Barraud N; Rice SA; Wang J; Li J; Chan HK
    Mol Pharm; 2015 Aug; 12(8):2594-603. PubMed ID: 25423590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Surface Composition on the Aerosolisation and Dissolution of Inhaled Antibiotic Combination Powders Consisting of Colistin and Rifampicin.
    Wang W; Zhou QT; Sun SP; Denman JA; Gengenbach TR; Barraud N; Rice SA; Li J; Yang M; Chan HK
    AAPS J; 2016 Mar; 18(2):372-84. PubMed ID: 26603890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Colistin powders with high aerosolisation efficiency for respiratory infection: preparation and in vitro evaluation.
    Zhou QT; Morton DA; Yu HH; Jacob J; Wang J; Li J; Chan HK
    J Pharm Sci; 2013 Oct; 102(10):3736-47. PubMed ID: 23904207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic antibiotic combination powders of colistin and rifampicin provide high aerosolization efficiency and moisture protection.
    Zhou QT; Gengenbach T; Denman JA; Yu HH; Li J; Chan HK
    AAPS J; 2014 Jan; 16(1):37-47. PubMed ID: 24129586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dry powder inhalation containing muco-inert ciprofloxacin and colistin co-loaded liposomes for pulmonary P. Aeruginosa biofilm eradication.
    Wang J; Guo Y; Lu W; Liu X; Zhang J; Sun J; Chai G
    Int J Pharm; 2024 Jun; 658():124208. PubMed ID: 38723731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhalable liposomal powder formulations for co-delivery of synergistic ciprofloxacin and colistin against multi-drug resistant gram-negative lung infections.
    Yu S; Wang S; Zou P; Chai G; Lin YW; Velkov T; Li J; Pan W; Zhou QT
    Int J Pharm; 2020 Feb; 575():118915. PubMed ID: 31816354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the antibiotic component on in-vitro bacterial killing, physico-chemical properties, aerosolization and dissolution of a ternary-combinational inhalation powder formulation of antibiotics for pan-drug resistant Gram-negative lung infections.
    Mangal S; Huang J; Shetty N; Park H; Lin YW; Yu HH; Zemlyanov D; Velkov T; Li J; Zhou QT
    Int J Pharm; 2019 Apr; 561():102-113. PubMed ID: 30797863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections.
    Lin Y; Chang RYK; Britton WJ; Morales S; Kutter E; Li J; Chan HK
    Eur J Pharm Biopharm; 2019 Sep; 142():543-552. PubMed ID: 31398437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic antibacterial effect of inhaled aztreonam and tobramycin fixed dose combination to combat multidrug-resistant Gram-negative bacteria.
    Wang J; Kutter JP; Mu H; Moodley A; Yang M
    Int J Pharm; 2020 Nov; 590():119877. PubMed ID: 32927003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Vitro Evaluation of Inhalable Verapamil-Rifapentine Particles for Tuberculosis Therapy.
    Parumasivam T; Chan JG; Pang A; Quan DH; Triccas JA; Britton WJ; Chan HK
    Mol Pharm; 2016 Mar; 13(3):979-89. PubMed ID: 26808409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved Physical Stability and Aerosolization of Inhalable Amorphous Ciprofloxacin Powder Formulations by Incorporating Synergistic Colistin.
    Shetty N; Ahn P; Park H; Bhujbal S; Zemlyanov D; Cavallaro A; Mangal S; Li J; Zhou QT
    Mol Pharm; 2018 Sep; 15(9):4004-4020. PubMed ID: 30028947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic combination dry powders for inhaled antimicrobial therapy: formulation, characterization and in vitro evaluation.
    Lee SH; Teo J; Heng D; Ng WK; Chan HK; Tan RB
    Eur J Pharm Biopharm; 2013 Feb; 83(2):275-84. PubMed ID: 23010564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Delivery of High-Dose Dry Powder Antibiotics by a Low-Cost Generic Inhaler.
    Parumasivam T; Leung SS; Tang P; Mauro C; Britton W; Chan HK
    AAPS J; 2017 Jan; 19(1):191-202. PubMed ID: 27679516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel inhaled multi-pronged attack against respiratory bacteria.
    Lee SH; Teo J; Heng D; Zhao Y; Ng WK; Chan HK; Tan LT; Tan RB
    Eur J Pharm Sci; 2015 Apr; 70():37-44. PubMed ID: 25612805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel inhalable form of rifapentine.
    Chan JG; Duke CC; Ong HX; Chan JC; Tyne AS; Chan HK; Britton WJ; Young PM; Traini D
    J Pharm Sci; 2014 May; 103(5):1411-21. PubMed ID: 24585270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro evaluation of novel inhalable dry powders consisting of thioridazine and rifapentine for rapid tuberculosis treatment.
    Parumasivam T; Chan JG; Pang A; Quan DH; Triccas JA; Britton WJ; Chan HK
    Eur J Pharm Biopharm; 2016 Oct; 107():205-14. PubMed ID: 27422209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repurposing ebselen as an inhalable dry powder to treat respiratory tract infections.
    Saha T; Lyons N; Yue Yung DB; Quiñones-Mateu ME; Pletzer D; Das SC
    Eur J Pharm Biopharm; 2024 Feb; 195():114170. PubMed ID: 38128743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection.
    Hengzhuang W; Wu H; Ciofu O; Song Z; Høiby N
    Antimicrob Agents Chemother; 2012 May; 56(5):2683-90. PubMed ID: 22354300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development, Characterization, and In Vitro Testing of Co-Delivered Antimicrobial Dry Powder Formulation for the Treatment of Pseudomonas aeruginosa Biofilms.
    Bahamondez-Canas TF; Ferrati S; Moraga-Espinoza DF; Smyth HDC
    J Pharm Sci; 2018 Aug; 107(8):2172-2178. PubMed ID: 29698726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and characterization of a spray-dried inhalable ternary combination for the treatment of Pseudomonas aeruginosa biofilm infection in cystic fibrosis.
    Alhajj N; Yahya MFZR; O'Reilly NJ; Cathcart H
    Eur J Pharm Sci; 2024 Jan; 192():106654. PubMed ID: 38013123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.